Research programme: histone deacetylase inhibitors - Menarini
Latest Information Update: 17 Mar 2008
At a glance
- Originator Menarini
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Mar 2008 Preclinical development is ongoing
- 13 Feb 2007 Preclinical trials in Cancer in Italy (unspecified route)